Patents Examined by Ali Salimi
-
Patent number: 6670118Abstract: The present invention discloses a method of treatment for patients having lesions resulting from papillomavirus infections by topically administering Product R, a peptide-nucleic acid preparation, to the lesions.Type: GrantFiled: November 10, 1998Date of Patent: December 30, 2003Assignee: Advanced Viral Research Corp.Inventor: Shalom Z. Hirschman
-
Patent number: 6642008Abstract: Compositions that bind specific viral proteins expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for infected cell removal. These antibodies can distinguish cells expressing EBV DNA from cells which do not. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also discloset.Type: GrantFiled: November 22, 2000Date of Patent: November 4, 2003Assignee: Oklahoma Medical Research FoundationInventors: John B. Harley, Judith Ann James, Kenneth M. Kaufman
-
Patent number: 6267965Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: GrantFiled: May 26, 1998Date of Patent: July 31, 2001Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffman
-
Patent number: 6261807Abstract: A novel method for preparing recombinant adenoviruses and the use of such adenoviruses in gene therapy are disclosed. Plasmids used in the construction of said adenoviruses are also disclosed.Type: GrantFiled: August 8, 1997Date of Patent: July 17, 2001Assignee: Rhone-Poulenc Rorer S.A.Inventors: Joël Crouzet, Laurent Naudin, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
-
Patent number: 6251403Abstract: This invention provides a recombinant swinepox virus comprising a foreign DNA sequence inserted into the swinepox virus genomic DNA, wherein the foreign DNA sequence is inserted within a HindIII M fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.Type: GrantFiled: June 7, 1995Date of Patent: June 26, 2001Assignee: Syntro CorporationInventors: Mark D. Cochran, David E. Junker
-
Patent number: 6221577Abstract: The invention relates to seroreactive regions on protein E1 and E2 of human papillomavirus (HPV) 16. The application also relates to a vaccine which contains such peptides which contain the seroreactive regions. The invention likewise embraces compositions for diagnostic purposes which contain peptides with the seroreactive regions.Type: GrantFiled: June 6, 1995Date of Patent: April 24, 2001Assignee: Dade Behring Marburg GmbHInventors: Martin Müller, Lutz Gissmann
-
Patent number: 6183750Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from herpesvirus. In one embodiment, the foreign DNA is expressed in a host by the production of a herpesvirus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two, particularly two or three, herpesvirus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, the barrier of maternal immunity in a newborn offspring can be overcome or avoided.Type: GrantFiled: June 7, 1995Date of Patent: February 6, 2001Assignee: Health Research, Inc.Inventor: Enzo Paoletti
-
Patent number: 6183746Abstract: The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.Type: GrantFiled: October 9, 1998Date of Patent: February 6, 2001Assignee: Zycos Inc.Inventors: Robert G. Urban, Roman M. Chicz, Edward J. Collins, Mary Lynne Hedley
-
Patent number: 6183753Abstract: This invention provides a recombinant herpesvirus of turkeys-Marek's disease virus chimera comprising a herpesvirus of turkeys unique long viral genome region and a Marek's disease virus unique short viral genome region.Type: GrantFiled: February 21, 1997Date of Patent: February 6, 2001Assignee: Schering-Plough Veterinary Corp.Inventors: Mark D. Cochran, Martha A. Wild, Barbara J. Winslow
-
Patent number: 6183751Abstract: This invention provides an isolated nucleic acid molecule which encodes Kaposi's Sarcoma-Associated Herpesvirus (KSHV) polypeptides. This invention provides an isolated polypeptide molecule of KSHV. This invention provides an antibody specific to the polypeptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a vaccine for Kaposi's Sarcoma (KS). This invention provides methods of vaccination, prophylaxis, diagnosis and treatment of a subject with KS and of detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.Type: GrantFiled: November 29, 1996Date of Patent: February 6, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventors: Yuan Chang, Roy A. Bohenzky, James J. Russo, Isidore S. Edelman, Patrick S. Moore
-
Patent number: 6180356Abstract: The invention relates to methods for identifying antimicrobial agents which inhibit bacterial toxin membrane pore formation and for treating diseases where bacterial protein toxins that form pores in membranes are virulence agents. The invention involves screening for small molecule agents which inhibit membrane pore formation by bacterial protein toxins. The invention is also a method for treating bacterial infection by inhibiting membrane pore formation by bacterial toxin using agents that inhibit membrane pore formation by bacterial toxins. The methods of the invention are also applicable for developing antiviral agents that treat viral infection where exposure of hydrophobic sites of proteins is associated with infection.Type: GrantFiled: March 6, 1998Date of Patent: January 30, 2001Assignee: The Research Foundation of State University of NYInventors: Erwin London, Juanita C. Sharpe
-
Patent number: 6177080Abstract: The invention relates to polypeptides of the Kaposi sarcoma-associated herpes virus which have a part-sequence of at least 10 consecutive amino acids from the sequence Met Ser Ser Thr Gln Ile Arg Thr Glu Ile Pro Val Ala Leu Leu Ile Leu Cys Leu Cys Leu Val Ala Cys His Ala Asn Cys Pro Thr Tyr Arg Ser His Leu Gly Phe Trp Gln Glu Gly Trp Ser Gly Gln Val Tyr Gln Asp Trp Leu Gly Arg Met Asn Cys Ser Tyr Glu Asn Met Thr Ala Leu Glu Ala Val Ser Leu Asn Gly Thr Arg Leu Ala Ala Gly Ser Pro Ser Ser Glu Tyr Pro Asn Val Ser Val Ser Val Glu Asp Thr Ser Ala Ser Gly Ser Gly Glu Asp Ala Ile Asp Glu Ser Gly Ser Gly Glu Glu Glu Arg Pro Val Thr Ser His Val Thr Phe Met Thr Gln Ser Val Gln Ala Thr Thr Glu Leu Thr Asp Ala Leu Ile Ser Ala Phe Ser Gly Val Leu His Val Ser Thr Val Ile Pro Arg Asn Trp Val Asn Arg Arg Cys Val Gly Ile Lys Arg Asn Leu Thr PheType: GrantFiled: July 8, 1998Date of Patent: January 23, 2001Assignee: Biotest AGInventors: Bernhard Fleckenstein, Jens-Christian Albrecht, Frank Neipel, Dieter Lang
-
Patent number: 6174532Abstract: The N-terminal region of bovine papillomavirus (BPV-4) L2 protein includes three immunogenically active epitopes. Two of these epitopes have substantial sequence homology to human papillomavirus (HPV) types. The BPV and HPV sequences are used to produce vaccine formulations for use in cattle and humans.Type: GrantFiled: May 12, 1997Date of Patent: January 16, 2001Assignee: Cancer Research Campaign Technology LimitedInventors: Maria Saveria Campo, William Fleming Hogan Jarrett
-
Patent number: 6171597Abstract: The present invention provides an AAV vector having a foreign DNA coding for a protein that boosts immunogenicity of cells. The invention also provides a vaccine containing such a vector and the use of both.Type: GrantFiled: May 5, 1999Date of Patent: January 9, 2001Assignee: Medigene AGInventors: Gerhard Maass, Michael Hallek, Christoph Bogedain
-
Patent number: 6171592Abstract: Equine rhinovirus 1 (ERhV1) is a respiratory pathogen of horses which has an uncertain taxonomic status. The nucleotide sequence of the ERhV1 genome and amino acid sequence have been substantially determined (FIG. 2). The predicted polyprotein was encoded by 6,741 nucleotides and possessed a typical picornavirus proteolytic cleavage pattern, including a leader polypeptide. The genomic structure and predicted amino acid sequence of ERhV1 were more similar to those of foot-and-mouth disease viruses (FMDV), the only members of the aphthovirus genus, than other picornaviruses. Nucleotide sequences coding for the complete polyprotein, the polymerase, and VP1 were analyzed separately. The phylogenetic trees confirmed that ERhV1 was more closely related to aphthoviruses than to other picornaviruses. Virion proteins and virus-like particles are described and probes, primers, antigens, vectors, diagnostics and tests developed.Type: GrantFiled: October 5, 1998Date of Patent: January 9, 2001Assignee: The University of MelbourneInventors: Michael J. Studdert, Brendan S. Crabb, Li Feng
-
Patent number: 6168915Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of a organisms to antimicrobial agents.Type: GrantFiled: April 24, 1998Date of Patent: January 2, 2001Assignees: Diagnostic Hybrids, Inc., University Hospitals of ClevelandInventors: David R. Scholl, Yung T. Huang, Patricia Gail Ray Goodrum
-
Patent number: 6165515Abstract: A therapeutic agent for osteoporosis brought about by a decrease in estrogen comprises an extract from inflammatory rabbit skin inoculated with vaccinia virus as an effective component. In ovariectomized rats, a model animal for osteoporosis brought about by a decrease in estrogen, the extract from inflammatory rabbit skin inoculated with vaccinia virus has an excellent action for maintaining bone volume and bone strength. The therapeutic agent containing the extract as an active component is very useful for treatment and prevention of osteoporosis brought about by a decrease in estrogen which is frequently caused by menopause or ovariectomy in women. The extract from inflammatory rabbit skin inoculated with vaccinia virus has a high safety profile even when administered for a long term.Type: GrantFiled: June 18, 1998Date of Patent: December 26, 2000Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Toshikatsu Matsuyama, Jin-emon Konishi
-
Patent number: 6165471Abstract: The present invention relates to stable HPV capsomeres which express at least one virus-neutralizing conformational epitope of a native HPV L1 protein which are substantially incapable of assembly into virus-like particles. These capsomeres, because of their smaller size, and immunogenic properties are well suited for use in HPV vaccines and as diagnostic agents. Moreover, because of their smaller size (relative to VLPs), these stable capsomeres may be easily purified and should result in HPV vaccines of enhanced homogeneity.Type: GrantFiled: July 2, 1998Date of Patent: December 26, 2000Assignees: University of Colorado, University Technology Corporation, MedImmune, Inc., University of Rochester, Office of Research and Project Administration and Institute of Higher EducationInventors: Robert L. Garcea, JoAnn A. Suzich, Michael P. McCarthy, Robert C. Rose
-
Patent number: 6159477Abstract: Disclosed and claimed is a recombinant canine herepes virus (CHV). The recombinant CHV includes and expresses at least one heterologous nucleotide sequence encoding an antigen. The antigen can be canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, or Borrelia burgdorferi OspB. The at least one heterologous nucleotide sequence can be in at least one insertion site selected from the group consisting of ORF3 (SEQ ID NO:4), ORF5 (SEQ ID NO:5), the thymidine kinase gene, and the intergenic region corresponding to genes coding for the large subunit and the small subunit. Immunological or vaccine compositions as well as methods for inducing an immunological response are also disclosed and claimed.Type: GrantFiled: December 16, 1998Date of Patent: December 12, 2000Assignee: MerialInventors: Jean-Christophe Audonnet, Philippe Baudu
-
Patent number: 6156498Abstract: A method establishes for the first time a HHV-8 producing immortalized lymphoma cell line, which is free of EBV, CMV, and HIV. Large quantities of uncontaminated HHV-8 are produced by the cells, and the virus or immunogenic fragments thereof are used to obtain specific polyclonal and monoclonal antibody. Assays and kits are useful for detecting viral infection in mammalian samples.Type: GrantFiled: May 14, 1998Date of Patent: December 5, 2000Assignee: Cedars-Sinai Medical CenterInventors: H. Phillip Koeffler, Jonathan W. Said